Myrtle Davis
Overview
Explore the profile of Myrtle Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou X, Levesque P, Chaudhary K, Davis M, Rodriguez B
Sci Rep
. 2024 Aug;
14(1):19921.
PMID: 39198564
No abstract available.
2.
Zhou X, Levesque P, Chaudhary K, Davis M, Rodriguez B
Sci Rep
. 2024 Jul;
14(1):17351.
PMID: 39075069
Chronic heart failure is one of the most common reasons for hospitalization. Current risk stratification is based on ejection fraction, whereas many arrhythmic events occur in patients with relatively preserved...
3.
Rockley K, Roberts R, Jennings H, Jones K, Davis M, Levesque P, et al.
Toxicol Sci
. 2023 Aug;
196(1):126-140.
PMID: 37632788
Seizure liability remains a significant cause of attrition throughout drug development. Advances in stem cell biology coupled with an increased understanding of the role of ion channels in seizure offer...
4.
Rusyn I, Sakolish C, Kato Y, Stephan C, Vergara L, Hewitt P, et al.
Toxicol Sci
. 2022 Jun;
188(2):143-152.
PMID: 35689632
Much has been written and said about the promise and excitement of microphysiological systems, miniature devices that aim to recreate aspects of human physiology on a chip. The rapid explosion...
5.
Gill M, Murphy B, Cheng P, Sivaraman L, Davis M, Lehman-McKeeman L
Toxicol Appl Pharmacol
. 2022 Jan;
438:115885.
PMID: 35090952
In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA) antagonist, produced hepatobiliary toxicity (increased ALT, AST, and ALP; cholecystitis) and increases in plasma bile acids (BA). Nonclinical...
6.
Pointon A, Maher J, Davis M, Baker T, Cichocki J, Ramsden D, et al.
Lab Chip
. 2021 Jan;
21(3):458-472.
PMID: 33471007
The integrative responses of the cardiovascular (CV) system are essential for maintaining blood flow to provide oxygenation, nutrients, and waste removal for the entire body. Progress has been made in...
7.
Hedrich W, Panzica-Kelly J, Chen S, Strassle B, Hasson C, Lecureux L, et al.
Toxicology
. 2020 Nov;
446:152614.
PMID: 33199268
Many in vitro gastrointestinal models have been developed with the hope that they will continue to improve in their similarity to the organs from which they were isolated. Intestinal organoids...
8.
Minasian L, Dimond E, Davis M, Adhikari B, Fagerstrom R, Fabian C, et al.
JACC CardioOncol
. 2020 Jun;
1(1):105-113.
PMID: 32529192
Cardiovascular (CV) toxicity from cancer therapy is a significant and growing concern. Conventional oncology clinical trial designs focused singularly on cancer treatment efficacy have not provided sufficient information on both...
9.
Phillips J, Grandhi T, Davis M, Gautier J, Hariparsad N, Keller D, et al.
Lab Chip
. 2020 Jan;
20(3):468-476.
PMID: 31989145
The human kidney contains approximately one million nephrons. As the functional unit of the kidney, the nephron affords an opportunity to approximate the kidney at a microphysiological scale. Recent emergence...
10.
Ainslie G, Davis M, Ewart L, Lieberman L, Rowlands D, Thorley A, et al.
Lab Chip
. 2019 Aug;
19(19):3152-3161.
PMID: 31469131
The lung is a complex organ; it is both the initial barrier for inhaled agents and the site of metabolism and therapeutic effect for a subset of systemically administered drugs....